journal article·2025-04Open access

Evaluation of Electrospun Poly‐4‐Hydroxybutyrate as Biofunctional and Degradable Scaffold for Pelvic Organ Prolapse in a Vaginal Sheep Model

Krista L. C. van Rest, Stephen T. Jeffrey, Lisa Kaestner, Aksel Gudde, Anel Oosthuysen, Jan‐Paul W. R. Roovers, Zeliha Guler

Macromolecular Bioscience· Volume 25· Issue 4

Abstract

Abstract Pelvic organ prolapse (POP) affects many women, especially after menopause. POP occurs due to the descent of weakened supportive tissue. Current prolapse surgeries have high failure rates, due to disturbed wound healing caused by lower tissue regeneration and estrogen depletion. Absorbable poly‐4‐hydroxybutyrate (P4HB) knit implants exhibited improved cell and tissue response leading to less complications from prolapse surgery. This study aims to enhance wound healing and improve surgical outcomes by using an electrospun (ES) P4HB scaffold (ES P4HB) that emulates natural tissue structure. Further 17β‐estradiol (E2)‐a prominent wound healing factor‐is incorporated into the scaffold (ES P4HB‐E2). Parous Dohne Merino sheep underwent posterior vaginal wall implantation of either P4HB (n = 6) or 17β‐estradiol relasing P4HB‐E2 (n = 6) scaffolds, or underwent native tissue repair (NTR) (n = 4). Vaginal explants were compared for short‐term host response in terms of gross necropsy, histomorphology, biomechanics, tissue‐integration, and degradation of P4HB at 3‐months post‐implantation. Both scaffolds show promising results with enhanced mechanical properties and increased macrophage infiltration compared to NTR, but without differences between scaffolds. Thus, it seems electrospun P4HB scaffolds already improve tissue integration and healing. Further long‐term studies are needed before these scaffolds can be used in clinical practice.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pelvic floor disorders treatments · Hernia repair and management · Enhanced Recovery After Surgery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Amsterdam UMC Location University of Amsterdam Department of Obstetrics and Gynecology Amsterdam 1105 AZ The Netherlands

Amsterdam Reproduction and Development Research Institute Amsterdam 1105 AZ The Netherlands

Department of Obstetrics and Gynecology Groote Schuur Hospital University of Cape Town Cape Town 7925 South Africa

Department of Urology Groote Schuur Hospital University of Cape Town Cape Town 7925 South Africa

Cardiovascular Research Unit Division of Cardiothoracic Surgery University of Cape Town Cape Town 7925 South Africa

References (49)

Show source-provided references
1. 10.1007/s00192-021-04953-110.1007/s00192-021-04953-1 ↗
2. 10.1007/s00192-022-05081-010.1007/s00192-022-05081-0 ↗
3. 10.1016/j.ajog.2011.03.04610.1016/j.ajog.2011.03.046 ↗
4. 10.1097/AOG.0b013e3181f7372910.1097/AOG.0b013e3181f73729 ↗
5. 10.3390/biom1201009410.3390/biom12010094 ↗
6. FDA takes action to protect women's health orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices https://www.fda.gov/news‐events/press‐announcements/fda‐takes‐action‐protect‐womens‐health‐orders‐manufacturers‐surgical‐mesh‐intended‐transvaginal(accessed: March2023).
7. 10.3390/jpm1406062210.3390/jpm14060622 ↗
8. Yeung E. · Cochrane Database Syst. Rev. · 2024 · 3
9. 10.1016/S0140-6736(16)31596-310.1016/S0140-6736(16)31596-3 ↗
10. 10.1590/S1677-5538.IBJU.2013.04.0810.1590/S1677-5538.IBJU.2013.04.08 ↗
11. 10.1007/s00192-010-1153-x10.1007/s00192-010-1153-x ↗
12. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) · 2015
13. 10.1111/1471-0528.1704010.1111/1471-0528.17040 ↗
14. 10.1007/s00192-023-05720-010.1007/s00192-023-05720-0 ↗
15. 10.1021/acsabm.2c0069110.1021/acsabm.2c00691 ↗
16. 10.1002/jbm.b.3436410.1002/jbm.b.34364 ↗
17. 10.1002/jbm.b.3515810.1002/jbm.b.35158 ↗
18. 10.1016/j.actbio.2020.01.04110.1016/j.actbio.2020.01.041 ↗
19. 10.1002/jbm.b.3387510.1002/jbm.b.33875 ↗
20. 10.1097/SPV.0b013e3181ab480410.1097/SPV.0b013e3181ab4804 ↗
21. 10.1002/nau.2397710.1002/nau.23977 ↗
22. 10.1016/j.euf.2017.05.00410.1016/j.euf.2017.05.004 ↗
23. 10.1002/nau.2481910.1002/nau.24819 ↗
24. 10.1016/j.msec.2020.11170210.1016/j.msec.2020.111702 ↗
25. 10.3390/polym1505124710.3390/polym15051247 ↗
26. 10.1002/jbm.b.3358610.1002/jbm.b.33586 ↗
27. 10.3390/polym1209202410.3390/polym12092024 ↗
28. 10.3389/fsurg.2023.115766110.3389/fsurg.2023.1157661 ↗
29. 10.1016/j.euf.2018.07.02410.1016/j.euf.2018.07.024 ↗
30. 10.3390/ma1207117410.3390/ma12071174 ↗
31. 10.1007/s10029-011-0885-y10.1007/s10029-011-0885-y ↗
32. 10.1111/1471-0528.1208110.1111/1471-0528.12081 ↗
33. 10.1002/nau.2467710.1002/nau.24677 ↗
34. 10.1016/j.jmbbm.2017.06.03210.1016/j.jmbbm.2017.06.032 ↗
35. 10.1016/j.ajog.2020.07.00510.1016/j.ajog.2020.07.005 ↗
36. 10.1016/j.actbio.2022.05.05110.1016/j.actbio.2022.05.051 ↗
37. 10.1016/j.biomaterials.2008.01.01110.1016/j.biomaterials.2008.01.011 ↗
38. 10.3390/ijms1903074510.3390/ijms19030745 ↗
39. 10.1089/ten.tea.2016.019410.1089/ten.tea.2016.0194 ↗
40. 10.1021/acs.biomac.8b0166110.1021/acs.biomac.8b01661 ↗
41. 10.1007/s00192-021-04851-610.1007/s00192-021-04851-6 ↗
42. 10.1042/CS2022053110.1042/CS20220531 ↗
43. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
44. 10.1177/2041731422114920710.1177/20417314221149207 ↗
45. 10.1002/path.410410.1002/path.4104 ↗
46. 10.3390/polym1612166710.3390/polym16121667 ↗
47. 10.1002/nau.2351010.1002/nau.23510 ↗
48. 10.1093/humrep/dei29610.1093/humrep/dei296 ↗
49. 10.1002/ijgo.1481610.1002/ijgo.14816 ↗